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Myocardial infarction survivors have an increased risk of stroke, which is reduced with long-term anticoagulant therapy. 
However, an estimated 10-times increase in risk of bleeding during such treatment has been reported. We evaluated 
the risk of stroke in patients after a myocardial infarction and examined the relationship of the risk of intracranial 
hemorrhage or cerebral infarction and the intensity of anticoagulant therapy. The study population consisted of 3,404 
post-myocardial infarction patients who took part in a randomized, double-blind, placebo-controlled trial. Patients 
were randomized to treatment with anticoagulants (international normalized ratio range, 2.8-4.8) or matching placebo. 
Mean follow-up was more than 3 years. The incidence of stroke analyzed on “intention-to-treat’’ was 0.7 per 100 
patient-years in the anticoagulant patients against 1.2 in placebo, a hazard ratio of 0.60, with 95% confidence interval 
of 0.40 to 0.90. In the anticoagulation group, 15 patients had cerebral infarction and 17 an intracranial bleeding, 3 of 
which occurred after withdrawal of treatment. In the placebo group, the numbers were 43 and 2. Of the 14 intracranial 
bleeds during anticoagulation, 6 occurred at an international normalized ratio between 3.0 and 4.0 and 8 at greater 
than 4.0. These results confirm that long-term anticoagulant therapy substantially reduces the risk of stroke in post- 
myocardial infarction patients. The increased risk of bleeding complications associated with anticoagulant therapy is 
offset by a marked reduction in ischemic events. The risk of intracranial bleeding is directly related to the intensity of 
anticoagulant treatment. 
Azar AJ, Koudstaal PJ, Wintzen AR, van Bergen I’F, Jonker JJ, Deckers JW. Risk of stroke during long- 
term anticoagulant therapy in patients after myocardial infarction. Ann Neurol 1996;39:30 1-307 
Survivors of myocardial infarction have an increased 
risk of thromboembolic events, including stroke, that 
has been estimated between 5% and 8% in the first 
year [ 11. Administration of long-term anticoagulant 
therapy may reduce the number of such events [2]. 
However, an estimated 10-times increase in risk of 
bleeding during such treatment has been reported [2- 
71. Approximately 50% of these bleedings are fatal [4]. 
The presence of hypertension, older age, and trauma 
has been associated with an increased risk of stroke [6]. 
The results of the three recently conducted post- 
myocardial infarction trials indicated a 40 to 55% re- 
duction in the risk of stroke in patients treated with 
anticoagulant therapy for 2 to 3 years compared with 
placebo [%lo]. The intensity of anticoagulant therapy 
in the three trials was targeted at 2.5 to 5.0 interna- 
tional normalized ratio (INR). The number of intra- 
cranial bleedings was higher in the anticoagulated 
group, but cerebral infarctions were more common in 
the placebo group. 
The purpose of this report is to describe the risk of 
stroke for post-myocardial infarction patients treated 
with long-term anticoagulant therapy. In addition, we 
examined the relationship of the risk of intracranial 
hemorrhage or infarction and the intensity of anticoag- 
ulant therapy. The study population comprised 3,404 
patients randomized to anticoagulant therapy or 
matching placebo. 
Patients and Methods 
Patients 
We studied post-myocardial infarction patients who took 
part in the ASPECT (Anticoagulants in the Secondary Pre- 
vention of Events in Coronary Thrombosis) trial. This trial 
has been described earlier [ 8 ] .  In short, ASPECT was a ran- 
domized, double-blind, placebo-controlled, multicenter clini- 
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cal trial that compared anticoagulant therapy with matching 
placebo on mortality and cardiovascular events in post-myo- 
cardial infarction patients. 
Hospital survivors of acute myocardial infarction were 
screened for eligibility just prior to hospital discharge. Pa- 
tients with an indication for oral anticoagulant therapy, in- 
cluding the presence of atrial fibrillation, left ventricular an- 
eurysm or thrombus, or with clinical overt evidence of heart 
failure at discharge, were not eligible. Informed consent was 
obtained in all subjects. Patients were randomly assigned to 
treatment with oral anticoagulant therapy or to matching 
placebo. From September 1, 1986, to December 31, 1991, 
3,404 patients were randomized. The study population con- 
tributed 10,441 patient-years of follow-up. 
Oral Anticoagulation and Dose Adjustment 
The target anticoagulant range was 2.8 to 4.8 INR [ll-151. 
Individual dose adjustments were guided by prothrombin 
time measurements obtained at regular intervals at specialized 
anticoagulant clinics, the Thrombosis Centers. Anticoagulant 
treatment consisted of phenprocoumon, acenocoumarol, or 
matching placebo tablets. Double-blinding was maintained 
by conversion of the actual prothrombin time values of pla- 
cebo-treated patients to fake values within therapeutic range 
by a computerized dosage algorithm at the anticoagulant 
clinic. 
At each follow-up visit to the anticoagulant clinic, a short 
history was taken and a blood sample drawn for determina- 
tion of the prothrombin time. The prothrombin time is the 
time needed for a blood sample to clot when a small quan- 
tity of thromboplastin reagent is added [15]. Patients were 
seen at the initial (ie, randomization) visit and on a weekly 
basis thereafter until the prothrombin time measurements 
were within the specified target range. The interval between 
visits was subsequently prolonged until a maximum period 
of 8 weeks. Patients requiring frequent dosage adjustments 
were seen more regularly. While on trial medication, patients 
were strongly advised not to take other antithrombotic medi- 
cation. At the end of the trial in June 1992, trial medication 
was discontinued in all patients. 
If available, prothrombin time measurements were ob- 
tained immediately before the hemorrhagic and nonhemor- 
rhagic episode. Otherwise, the last measurement within a 
maximum time frame of 28 days prior to the stroke was 
registered. 
Clinical Events 
Information on clinical events was obtained directly from 
the patients when they visited the Thrombosis Center or 
from their general practitioners. In case of hospitalization, 
additional information was retrieved from the hospital rec- 
ords. 
Stroke was diagnosed according to internationally ac- 
cepted criteria for the assessment of cerebrovascular disease 
[16]. Brief attacks lasting less than 24 hours and leaving no 
residual symptoms were classified as transient ischemic at- 
tacks (TIAs) [16j. If neurological death occurred within 24 
hours, a diagnosis of intracranial bleeding was made unless 
findings on computed tomographic (CT~I scanning indicated 
otherwise. Events lasting beyond 24 hours were specified as 
cerebral infarction or intracranial bleeding on the basis of 
C T  scanning, if available. If a CT scan was not available, 
the event was classified as unspecified. The diagnosis and 
classification of clinical events was made by two neurologists 
(P.J.K., A.R.W.), who independently reviewed the clinical 
course of each case on the basis of a standardized patient 
report. The committee members also registered and coded 
all neurological admissions. They were blinded to treatment 
assignment and were not informed of actual prothrombin 
time measurements. No distinction was made between pri- 
mary intracerebral hemorrhage and hemorrhagic infarction. 
The functional outcome of all cerebrovascular events was 
classified as survival with no disability, survival with mild 
disability (residual symptoms, but without impact on daily 
activities), survival with moderate disability (symptoms sig- 
nificantly interfering with normal daily activities, the patient 
being unable to live independently), survival with severe dis- 
ability (patient completely dependent in all activiries of daily 
living), or death. Other neurological nonvascular complica- 
tions diagnosed i n  the course of the trial included cerebral 
tumor (1 1 patients), Guillain-Bar& syndrome, lumbar disk 
hernia (20 patients), motor neuron disease (1 1 patients), and 
polyneuropathy (3 patients). 
Data Analysis 
A comparison between the anticoagulated and placebo 
groups with respect to the incidence of stroke was made in 
terms of the hazard ratio, ie, the risk of stroke per unit time 
for patients randomly assigned to oral anticoagulant therapy 
divided by the risk for those randomly assigned to placebo. 
Hazard ratios were obtained with the Cox proportional haz- 
ards model [ 171. The precision of the estimates was described 
with their 95% confidence intervals. For “intention-to-treat’’ 
analysis, all randomized patients were included irrespective 
of discontinuation of trial medication. Censoring was applied 
when the patient died, had a stroke, or at the end of follow- 
up, on June 30, 1992. In a subsidiary analysis, only those 
strokes that occurred while the patient was on trial treatment 
(or within 28 days after its cessation) were taken into account 
(“per-protocol” analysis). 
Results 
Demographic data, smoking habits, medical history, 
a n d  medication used during hospitalization are pre- 
sented in Table  1. The median age of the patients was 
61 years and  80% of the study population were men. 
As evidenced by their low prevalence of heart failure 
(only 5% in  Killip class I11 or  IV) at  any time during 
their hospitalization, and  a small number  (9O/o) with a 
previous myocardial infarction, ASPECT patients were 
representative of a relatively low-risk post-myocardial 
infarction population. 
Trial treatment was discontinued in  1,655 patients 
(768 after anticoagulant therapy and  887 i n  placebo). 
Reasons for discontinuation were vascular events (485 
patients: 2 15 anticoagulant therapy and  270 placebo) 
a n d  nonmedical in the 1,170 other patients (553 anti- 
302 Annals of Neurology Vol 39 No 3 March 1996 
Table I .  Selected Demographic, Baseline, and Randomization Characteristics 
~ 
Anticoagulant Placebo Total 
(n = 1,700) (YO) (n = 1,704) (YO) (n = 3,404) (Yo) 
55-65 
> 65 
Male 
Previous MIa 
Previous use of AC" 
Hematocrit (245) 
Killip IIIlIV 
History of DM 
Current smokers 
Treatment 
P-blockers 
Acetyl salicylic acid" 
Mean SBP, mm Hg (SD) 
507 (30) 490 (29) 997 (29) 
536 (32) 573 (33) 1,109 (33) 
657 (38)  64 1 (38) 1,298 (38)  
1,370 
157 
35 
735 
96 
134 
8 94 
8 67 
I18 
119 
1,350 
150 
44 
767 
93 
125 
888 
869 
104 
119 
2,720 
307 
79 
1,502 
189 
259 
1,782 
1,736 
222 
119 
-~~~ ~ 
'Prior to the qualifying myocardial infarction. 
bDiscontinued at randomization. 
MI = myocardial infarction; AC = anticoagulant; D M  = diabetes mellitus; SBP = systolic blood pressure at discharge; SD = standard 
deviation. 
~ anticoaguiation (AC) 
1180 886 538 258 
placebo 1477 1162 862 529 244 
80% I 
0 1 2 3 4 5 
time (years) 
Kaplan-Meier curves for stroke JFom any cause, according to 
assigned therapy. Numbers denote patients at risk (anticoagu- 
lated patients on top). 
coagulant therapy and 617 placebo). For the overall 
duration of the trial, patients received trial medication 
for 71% of the time in the anticoagulated and 67% 
in the placebo group. 
The time lapse between randomization and onset of 
stroke, analyzed on an intention-to-treat basis, is pre- 
sented in the Figure. The duration of treatment ranged 
from 1 day to 6 years. Three years following random- 
ization, 2% of the patients on anticoagulant therapy 
had suffered a stroke compared with 4% in placebo. 
The incidence of stroke analyzed on intention-to- 
treat and per-protocol analysis is presented in Table 2. 
Based on the total observation time (intention-to- 
treat), 99 patients were diagnosed as having a stroke. 
The risk of stroke increased with age; patients in the 
highest age tertile (>65 years) accounted for more than 
50% of all strokes. The incidence of stroke was margin- 
ally but not statistically significantly higher in patients 
with a previous myocardial infarction (I 1.1 % vs 8.1 Yo) 
and with heart failure (Killip class 3 or 4 )  during hospi- 
talization (5.5% vs 4.0°/o), and in patients (n = 100) 
developing arrhythmias following discharge (3.0% vs 
2.9%). The incidence of stroke was 0.7 per 100 pa- 
tient-years in the anticoagulated group and l .2 per 100 
patient-years in placebo, a hazard ratio (HR) of 0.60 
with a 95% confidence interval (CI) of 0.40 to 0.90, 
a 40% reduction in the risk of stroke in the anticoagu- 
lated group. 
The risk of hemorrhages was eight times greater for 
anticoagulated patients compared with placebo. Of the 
17 with intracranial bleeding in the anticoagulated 
group, 15 were diagnosed on the basis of a CT scan 
(9 intracerebral, 3 subdural, and 3 subarachnoidal). 
Eight of the 17 bleedings were fatal; 6 were diagnosed 
by CT scan (3 intracerebral, 2 subdural, and 1 sub- 
arachnoidal) and 2 on the basis of death within 24 
hours. Of the 2 with intracranial bleeding in the pla- 
cebo group, 1 was subdural and I undefined. No fatal 
intracranial bleeding occurred in the placebo group. 
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Table 2. Incidence o f  Stroke in the ASPECT Trial 
Anticoagulant 
(n = 1,700) 
Placebo 
(n = 1,704) HR (95% CI) 
Intention to treat 
Patient-years (py) of follow-up 
First stroke 
Intracranial bleeding 
Fatal 
Nonfatal 
Fatal 
Nonfatal 
Transient ischemic attack 
Unspecified 
Fatal 
Nonfatal 
Cerebral infarction 
Per protocol 
Patienr-years (py) of follow-up 
First stroke 
Intracranial bleeding 
Fatal 
Nonfatal 
Fatal 
Nonfatal 
I ransient ischemic attack 
Unspecified 
Fatal 
Nonfatal 
Cerebral infarction 
~~ 
5,241 
37 (0.7/100 py) 
17 
8 
9 
15 
L 
13 
2 
4 
1 
3 
3,725 
24 (0.61’100 py) 
14 
7 
L 
5,200 
62 (1.2/100 py) 0.60 (0.4-0.9) 
2 
0 
2 
43 
2 
41 
6 
12 
6 
6 
3,488 
1 
0 
1 
28 
42 (1.2/100 py) 
L 
26 
6 
7 
1 
6 
0.57 (0.34-0.93) 
~~ 
ASPECT = Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis; HR = hazard ratios; CJ = confidence intervals. 
Table 3. Functional Outcome o f  Stroke Survivors 
Bleeding Infarction TIA Unspecified 
AC PL AC PI, AC PL AC PL 
- 
No. of survivors 9 2 13 41 2 6 3 6 
Disability 
None 2 2 5 11 2 6 2 3 
Mild 4 0 4 13 0 0 1 1 
Moderate 1 0 4 8 0 0 0 1 
Severe 2 0 0 9 0 0 0 1 
AC = anticoagulant; PL = placebo; TIA = transient ischemic attacks. 
The functional outcome of the patients who survived 
a stroke is indicated in Table 3. Sixty-seven percent of 
the anticoagulated patients who survived a hemorrhagic 
bleeding were mildly or not disabled, compared with 
100% for placebo. 
The incidence of cerebral infarction was approxi- 
mately three times higher in the placebo than the anti- 
coagulated group. Sixty-nine percent of the anticoagu- 
lated patients who survived an infarction were mildly 
or not disabled, compared with 599’0 for placebo. 
Six patients in the anticoagulation and 18 in the 
placebo group had an unspecified event or TIA. Six 
fatal events occurred in the placebo group, versus one 
in the anticoagulation group. All patients in the antico- 
agulant group who survived an unspecified stroke were 
mildly or not disabled, compared with 67% for pla- 
cebo. 
When all strokes were combined, the following fig- 
ures were obtained: The number of patients who died 
or were severely disabled amounted to 13 in the antico- 
agulation group, versus 18 in the placebo group. When 
moderately disabling stroke was included, these figures 
were 18 and 27, respectively. 
Among the 24 patients with a stroke in the actively 
treated group in the per-protocol analysis, prothrombin 
times were obtained shortly before or within 1 month 
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Table 4. Incidence o f  Stroke in the Sixy-Plus and WARIS Trial3 
SixqJ-Plus WARIS 
An ticoagulant Placebo H R  (95Yn CI) Anticodguldnc Placebo RR (959’~ CI) 
No. of patients 439 439 607 
Patient-years (py) of follow-up 878 878 1,872 
Stroke 12 (1.4/100 py) 20 (2.31100 py) 0.60 (0.30; 1.21) 20 (1.1/100 py) 
Intracranial bleeding 9 I 6 
Fatal 5 1 4 
Nonfatal 4 0 2 
Intracranial infarction 2 13 14 
Fatal 1 5 0 
Nonfatal 1 8 14 
Unspecified 1 6 
Fatal 0 0 
Nonfatal 1 6 
- 
607 
1,872 
0 
0 
0 
44 
10 
34 
44 (2.4/100 py) 0.45 (0.23; 0.76) 
- 
prior to the stroke in 17 and 21 patients, respectively. 
Of the 14 patients with intracranial bleeding, 6 were 
within the INR range of 3.0 to 4.0 and 8 had an INR 
of >4.0. N o  intracranial bleeding occurred between 
INR 2.0 and 3.0. Of the 7 with nonhemorrhagic 
strokes, 2 had an INR of <2, 3 had an INR of 3.0 
to 4.0, 1 had an INR of >4.0, and no measurement 
was available in 1 patient. 
Discussion 
These results indicate and confirm that long-term anti- 
coagulant therapy substantially reduces the risk of 
stroke in post-myocardial infarction patients. Al- 
though the treatment was associated with increased risk 
of bleeding complications, this was offset by a marked 
reduction of ischemic events. 
A comparison of strokes observed in the two most 
recently published secondary prevention trials is given 
in Table 4. The “Sixty-Plus” reinfarction trial ran- 
domly allocated patients already treated with oral anti- 
coagulant therapy to continuation (439 patients) or 
discontinuation (439 patients) of treatment [2,  91. The 
Warfarin Reinfarction trial (WARIS) randomized 
1,214 patients with a recent myocardial infarction to 
either anticoagulant therapy or placebo [ 101. The inci- 
dence of stroke in these as well as the current trial was 
reduced by 40%, to 55%, in favor of the anticoagulant 
group. The incidence in the anticoagulated patients 
was lowest (0.7 per 100 patient-years) in the ASPECT 
population and highest (1.4/ 100 patient-years) in the 
Sixty-Plus trial. The incidence of stroke with placebo 
was similar in both the Sixty-Plus and WARIS (2.3/ 
100 patient-years) trials and was again lowest in the 
ASPECT group ( 1 2  100 patient-years). In the Sixty- 
Plus trial, a substantial, higher number of deaths was 
observed compared with the other two studies. This 
may be attributed to both the selection of patients as 
well as new treatment modalities, including thrombo- 
lytic therapy and increased frequency of revasculariza- 
tion in patients with myocardial infarction in the more 
recent ASPECT trial. 
In all three trials, intracranial bleeding occurred 
more frequently in the anticoagulated group than in 
the placebo group. The rate of hemorrhagic stroke (fa- 
tal or nonfatal) in the anticoagulated group was 0.3/ 
100 patient-years in both the WARIS and the AS- 
PECT trials but higher (1.0/100 patient-years) in the 
Sixy-Plus trial. For placebo-treated patients, the risk 
was lowest in the WARIS trial (0 patients), amounted 
to 0.04/100 patient-years in the ASPECT trial, and 
was again highest (0.1 / I00 patient-years) in the Sixty- 
Plus trial. 
A total of 35 hemorrhagic strokes were observed in 
the three trials, ie, 32 in the anticoagulated group, of 
which 17 were fatal, and 3 in the placebo group, of 
which 1 was fatal. The risk of hemorrhagic stroke ob- 
served in the three trials in the treated group was there- 
fore 0 . 4  100 patient-years against 0.041 100 patient- 
years in the placebo group. Thus, the incidence of 
hemorrhagic stroke in the anticoagulated patients was 
10 times higher than in untreated patients. Further- 
more, about 50% of the hemorrhagic strokes were fa- 
tal. In two population studies conducted in The Neth- 
erlands, a similar 8- to 10-times increase in the risk 
of intracranial hemorrhage in long-term anticoagulated 
patients older than 50 years, compared with the total 
population, was reported [4,  61, with at least 50% of 
these being fatal [2-4, 6, 71. 
Ischemic strokes (excluding the category unspecified) 
occurred more frequently in the placebo group than in 
the anticoagulated group. Fatal ischemic stroke oc- 
curred more often in untreated patients than in treated 
patients in two of the three studies [2, l o ]  and was 
equally frequent in both treatment groups in the pres- 
ent trial. A total of 31 cerebral infarctions occurred in 
the three trials in the anticoagulated group compared 
with 100 in the placebo group. A combined incidence 
of 0.4/100 patient-years in the treaced group and of 
1.3/100 patient-years in the placebo group was ob- 
WARIS = Warfarin Reinfarction trial; H R  = hazard ratios; CI = confidence intervdls; KR = rate ratios. 
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served. This finding indicates that untreated patients 
have at least a threefold increased risk of ischemic 
stroke compared with treated patients. Therefore, de- 
spite a 10-fold risk of bleedings in anticoagulated pa- 
tients, the overall outcome of patients treated with an- 
ticoagulation was better than with placebo. In patients 
on anticoagulants, 18 patients who suffered a stroke 
had either died or were moderately to severely disabled, 
against 27 in the placebo group in the current AS- 
PECT trial. 
Intracranial bleeding has been reported to occur 
more frequently with increased [3,  6, 18-24], and in- 
farction with lower [2, 22-24], anticoagulant intensi- 
ties. The therapeutic range for the two Dutch trials was 
2.5 to 5.0 INR. In the present study, no intracranial 
bleedings occurred at INR intensities between 2.0 and 
3.0, 6 bleeds occurred between INR 3.0 and 4.0, and 
8 occurred at intensities above 4.0 INR. These findings 
extend the previous observations and indicate that, for 
reasons of safety, the intensity of anticoagulant therapy 
should not exceed INR 4.0. 
Some elements of the current trial and its analysis 
deserve particular attention. First, ASPECT was a pla- 
cebo-controlled trial, and the described results are 
therefore not indicative of the effects of oral anticoagu- 
lation relative to treatment with aspirin. Unfortunately, 
as of yet, there are no large trials in post-myocardial 
infarction patients that have compared the two treat- 
ment modalities directly, and the answer to the relative 
efficacy of these treatment options must await results 
of currently ongoing trials. Although most cardiolo- 
gists, in the United States as we11 as in Europe, prefer 
the easy-to-use aspirin over the frequent monitoring 
associated with anticoagulant therapy, indirect evidence 
suggests that the anticoagulant agents may be better. 
Pooled results of the Antiplatelet Trialists group 
showed a 12% reduction in mortality, 31% reduction 
in myocardial infarction, and 39% reduction in strokes 
[25]. Pooled results of anticoagulant trials showed a 
19% mortality reduction, 44% reduction in both myo- 
cardial infarction and in stroke 1241. Indirect support 
for better effectiveness is also obtained from findings 
in patients with atrial fibrillation where oral anticoagu- 
lation was generally found to be more effective than 
aspirin in preventing stroke [26, 271. 
Some limitations of our study should be mentioned. 
As a result of its design, information gathered following 
hospital discharge was limited to clinical events, and 
we were therefore unable to assess the influences of 
changes in, for instance, smoking habits or blood pres- 
sure during follow-up that could have modified the 
subsequent risk for stroke. For the same reason, we 
were unable to speculate on the relation of the cardiac 
status and the risk for thromboembolic stroke. How- 
ever, since 95% of the patients were without evidence 
of heart failure at randomization, we must assume that 
most thromboembolic complications were not associ- 
ated with specific baseline cardiac abnormalities. An- 
other limitation concerns the analysis of the CT scans, 
which were not centrally reviewed; ie, no distinction 
could be made between intracerebral hemorrhage and 
hemorrhagic infarction. Although no patients were lost 
to follow-up, 30% of our patients discontinued prema- 
turely trial medication. There were two reasons for this 
relatively high dropout rate. First, the duration of the 
trial (6 years) was longer than anticipated, which 
prompted the refusal of patients to continue trial medi- 
cation. Second, with the upcoming popularity of aspi- 
rin during the course of the trial, most patients who 
survived a vascular event were subsequently treared 
with oral anticoagulant therapy or aspirin. This also 
explains the modest reduction in mortality as observed 
in this trial. However, we do not believe that the valid- 
ity of our results was effected by the dropout rate. This 
is attested by the results of the data, which were ana- 
lyzed using both the intention-to-treat and the per- 
protocol analysis, both yielding similar results. 
In conclusion, long-term anticoagulant therapy sub- 
stantially reduced the risk of stroke in post-myocardial 
infarction patients. Although the rate of intracranial 
bleeding, the most serious complication of anticoagu- 
lant therapy, was increased at least 10-fold, this was 
offset by a marked reduction in ischemic events of 
comparable functional outcome. The risk of intracra- 
nial bleeding was directly related to the intensity of 
anticoagulant treatment. Approximately 60% of the 
hemorrhagic strokes occurred at an INR of >4, and 
this value should therefore be considered the upper 
limit for safe oral anticoagulant therapy. 
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